<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03650335</url>
  </required_header>
  <id_info>
    <org_study_id>ESP</org_study_id>
    <nct_id>NCT03650335</nct_id>
  </id_info>
  <brief_title>Effect of Bupivacaine in Ultrasound-guided Erector Spinae Plane</brief_title>
  <official_title>Effect of Two Different Volumes of Bupivacaine 0.25% Used in Ultrasound-guided Erector Spinae Plane (ESP) Block on Dermatome Spread: A Volume Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuzuncu Yıl University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuzuncu Yıl University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of two different volumes of bupivacaine 0.25% used in
      ultrasound-guided erector spinae plane (ESP) block on dermatome spread and postoperative
      analgesia in patients undergoing unilateral thoracotomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will have a double-blind design and will be conducted after obtaining an approval
      from the local ethics committee. The study will include 50 patients planned for thoracotomy,
      aged 18-65 years with an ASA score of I-II. The patients will be randomized by sealed tender
      and will be divided into 2 groups with 25 patients each. Patients that will be transferred to
      the intensive care unit (ICU) intubated after the surgery, patients with a body mass index of
      35 or over, patients detected with infection in the intervention site, patients with
      hematological diseases, patients with a known allergy to local anesthetics, patients that
      will not provide a written or verbal consent, pregnant patients, and patients with an ASA
      score of III or IV will be excluded from the study. All the patients will undergo physical
      examination and their laboratory parameters will be evaluated one day prior to the procedure.
      Moreover, on the same day, each patient will be informed about dermatome testing (hot/cold),
      pain prick test (pain test), and pain pump set. Age, body height and weight, duration of
      block, and duration of surgery will be recorded for each patient
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2019</start_date>
  <completion_date type="Anticipated">December 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative opioid consumption</measure>
    <time_frame>First 24 hours total opioid consumption</time_frame>
    <description>Total opioid consumption as microgram/kg will be assessed in 24 hour surgery</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Thoracotomy</condition>
  <arm_group>
    <arm_group_label>group I</arm_group_label>
    <description>with a total of 20 mL 0.25% bupivacaine injection to be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group II</arm_group_label>
    <description>with a total of 30 mL 0.25% bupivacaine injection to be administered</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing thoracotomy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective thoracotomy

          -  Aged 18-65 years

          -  ASA score of I and II

        Exclusion Criteria:

          -  Patients that will be transferred to the intensive care unit (ICU) intubated after the
             surgery,

          -  Patients with a body mass index of 35 or over,

          -  Patients detected with infection in the intervention site,

          -  Patients with hematological diseases,

          -  Patients with a known allergy to local anesthetics,

          -  Patients that will not provide a written or verbal consent,

          -  Pregnant patients

          -  Patients with an ASA score of III or IV will be excluded from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>celaleddin soyalp</last_name>
    <role>Study Chair</role>
    <affiliation>Yuzuncu Yil University Dursun Odabas Medical School Anesthesiology and Reanimation Department Van, Turkey</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Celaleddin Soyalp</last_name>
    <phone>+905068456504</phone>
    <email>c.soyalp@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nureddin Yuzkat</last_name>
    <phone>+905052294728</phone>
    <email>nyuzkat@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Celaleddin Soyalp</name>
      <address>
        <city>VAN</city>
        <zip>65080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celaleddin soyalp</last_name>
      <phone>+905068456504</phone>
      <email>c.soyalp@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nureddin Yuzkat</last_name>
      <phone>+905052294728</phone>
      <email>nyuzkat@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yuzuncu Yıl University</investigator_affiliation>
    <investigator_full_name>Celaleddin Soyalp</investigator_full_name>
    <investigator_title>Assist .Prof.</investigator_title>
  </responsible_party>
  <keyword>erector spine plan block</keyword>
  <keyword>postoperative opioid consumption</keyword>
  <keyword>thoracotomy</keyword>
  <keyword>analgesia</keyword>
  <keyword>anesthesia</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

